Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

 Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

Johnson & Johnson Publishes Results of COVID-19 Single Shot Vaccine in NEJM

Shots:

  • The P-III ENSEMBLE trial involves assessing COVID-19 vaccine vs PBO in 43,783 enrolled participants aged ≥18yrs. with both mod. and sev. COVID-19 disease
  • The trial met all 1EP & 2EPs i.e 85% efficacy in preventing disease, vaccine efficacy was consistent against symptomatic infection including in South Africa and Brazil that showed a high prevalence of SARS-CoV-2 variants
  • Additionally, the trial met its co-1EPs of protecting against mod. to sev. COVID-19 that showed 67% efficacy @14days and 66 % efficacy @28days after vaccination. The vaccine demonstrated efficacy as early as 7days after vaccination, with efficacy continuing to increase 8wks. post-vaccination

Click here to­ read full press release/ article | Ref: J&J | Image: Market Watch

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post